Alefacept for the treatment of psoriasis and other dermatologic diseases.
Alefacept is a novel biologic agent for the treatment of plaque psoriasis. Alefacept is a fully human recombinant dimeric fusion protein composed of the terminal portion of Leukocyte Functioning Antigen-3 (LFA-3) and the Fc portion of human IgG(1). The drug likely works in part by inducing the apoptosis of memory effector (activated) T cells that play a central role in the pathophysiology of psoriasis. Alefacept also may interrupt the direct immunologic activation of T cells by antigen presenting cells. Alefacept is administered as a course of 12 intramuscular injections, but other dosing strategies have been explored. After a course of therapy, statistically more patients receiving alefacept achieve a psoriasis area and severity index (PASI) 75 response than those receiving a placebo. Some patients who achieve PASI 75 also experience long-term remissions from psoriasis. The drug is well-tolerated and adverse events are rare. Off-label use of the drug is growing and may be formally explored in the future.
Strober
Bruce E
BE
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA. Strober@nyc.rr.com
Menon
Kavita
K
D000077944:Alefacept; D004359:Drug Therapy, Combination; D017048:Health Care Costs; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
D011993:Recombinant Fusion Proteins; D000077944:Alefacept